CardiolRx not checked

Cardiol Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
13 active
27 in total · 26 in the EU
Targets
GPR55 · 5-HT1A · CB2 · CB1
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The intervention will be administered orally (via syringe) with food twice daily.”In the company’s words, NCT06708299 on ClinicalTrials.gov
Tested for
Recurrent Pericarditis
Main trialPhase 3
“Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.”In the company’s words, NCT06708299 on ClinicalTrials.gov
Other names
Pharmaceutically produced Cannabidiol · Cannabidiol

Other drugs for Recurrent Pericarditis

All 4 drugs for Recurrent Pericarditis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials27

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 21 Sep 2026 CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Phase 2/3Terminated 30 Nov 2022 Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Phase 2Completed 15 Jun 2024 Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Phase 2Completed 31 Jan 2025 Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
Phase 2Authorised not given Open-label pilot study to assess the efficacy and safety of Cannabidiol oral solution as an adjunctive treatment for children and young adults with rare disease-associated severe epilepsy
Phase 2Not authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 2Not authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 2Authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 3Not authorised not given Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
Phase 3Authorised not given Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
Phase 2Ended not given Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 30 and 700 mg in healthy male subjects on CNS and cortical excitability using the NeuroCart test battery and TMS.
Phase 2Authorised not given Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan)
Phase 2Authorised not given A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinoma - the CanHep study
Phase 2Ended not given Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study.
Phase 2Ended not given A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001
Phase 2Ended not given BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms
Phase 2Halted not given CBD-ESPRIT - Enhancing recovery in early schizophrenia – a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment
Phase 2/3Ended not given Cannabidiol for treatment of non-affective psychosis and cannabis use
Phase 2Ended not given Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study
Phase 2Authorised not given ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence
Phase 2Ended not given The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials
Phase 2Authorised not given CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II trial
Phase 2Authorised not given The effect of CBD on sleep quality following late evening exercise
Phase 2Authorised not given PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial
Phase 3Authorised not given Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series
Phase 2Authorised not given CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
Phase 3Authorised not given AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CardiolRx

Following is part of Solo: you see every change to CardiolRx the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in